HUP9901418A2 - Procedure for the racemization of levobupivacaine and analogous active substances - Google Patents

Procedure for the racemization of levobupivacaine and analogous active substances

Info

Publication number
HUP9901418A2
HUP9901418A2 HU9901418A HUP9901418A HUP9901418A2 HU P9901418 A2 HUP9901418 A2 HU P9901418A2 HU 9901418 A HU9901418 A HU 9901418A HU P9901418 A HUP9901418 A HU P9901418A HU P9901418 A2 HUP9901418 A2 HU P9901418A2
Authority
HU
Hungary
Prior art keywords
levobupivacaine
racemization
procedure
active substances
compound
Prior art date
Application number
HU9901418A
Other languages
Hungarian (hu)
Inventor
Ulrich Conrad Dyer
Marianne Langston
Martin Woods
Original Assignee
Darwin Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Limited filed Critical Darwin Discovery Limited
Publication of HUP9901418A2 publication Critical patent/HUP9901418A2/en
Publication of HUP9901418A3 publication Critical patent/HUP9901418A3/en
Publication of HU227426B1 publication Critical patent/HU227426B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Rolling Contact Bearings (AREA)
  • Optical Head (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány szerinti eljárás sőrán egy őptikailag feldúsítőtt, adőttesetben N-alkilezett piperidin-2-karbőxanilid-vegyületet őly módőnracemizálnak, hőgy a vegyületet vizes közegben melegítik, azzal amegkötéssel, hőgy a közeg egy szerves társőldószert is tartalmaz, ha avegyület N-alkilezett. A találmány szerinti eljárás egy rezőlválásieljárással kőmbinálva különösen jól alkalmazható a levőbűpivakainelőállítására. ŕAccording to the process according to the invention, an optically enriched, N-alkylated piperidine-2-carboxanilide compound in the donor body is racemized by heating the compound in an aqueous medium, with the proviso that the medium also contains an organic co-solvent if the compound is N-alkylated. The method according to the invention, combined with a grinding process, can be particularly well used for the production of the contained witch hazel. ŕ

HU9901418A 1995-01-18 1996-01-12 Racemisation process for use in the manufacture of levobupivacaine and related analogous agents HU227426B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501071.6A GB9501071D0 (en) 1995-01-18 1995-01-18 Racemisation
PCT/GB1996/000067 WO1996022281A1 (en) 1995-01-18 1996-01-12 Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents

Publications (3)

Publication Number Publication Date
HUP9901418A2 true HUP9901418A2 (en) 1999-08-30
HUP9901418A3 HUP9901418A3 (en) 2001-01-29
HU227426B1 HU227426B1 (en) 2011-05-30

Family

ID=10768271

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901418A HU227426B1 (en) 1995-01-18 1996-01-12 Racemisation process for use in the manufacture of levobupivacaine and related analogous agents

Country Status (20)

Country Link
EP (1) EP0804417B1 (en)
JP (1) JP4015696B2 (en)
KR (1) KR100404390B1 (en)
CN (1) CN1172912C (en)
AT (1) ATE242214T1 (en)
AU (1) AU701221B2 (en)
BR (1) BR9606821A (en)
CA (1) CA2208522C (en)
DE (1) DE69628540T2 (en)
DK (1) DK0804417T3 (en)
ES (1) ES2201166T3 (en)
FI (1) FI117437B (en)
GB (1) GB9501071D0 (en)
HU (1) HU227426B1 (en)
MX (1) MX9705428A (en)
NO (1) NO308843B1 (en)
PL (1) PL184091B1 (en)
PT (1) PT804417E (en)
WO (1) WO1996022281A1 (en)
ZA (1) ZA96403B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (en) 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Process for obtaining the enantiomers of racemic bupivacaine, process for obtaining pharmaceutical compositions based on levobupivacaine: pharmaceutical compositions based on levobupivacaine formulated in basic forms or pharmaceutically acceptable salts and use of pharmaceutical compositions based on levobupivacaine formulated in basic forms or pharmaceutically salts acceptable
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (en) 2002-12-13 2010-10-15 Durect Corp ORAL DOSAGE FORM WITH HIGH VISCOSITY LIQUID CARRIER SYSTEMS
SI2415484T1 (en) 2004-09-17 2014-10-30 Durect Corporation Sustained local anesthetic composition containing SAIB
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
JP2011506319A (en) 2007-12-06 2011-03-03 デュレクト コーポレーション Useful methods for the treatment of pain, joint inflammation symptoms, or inflammation associated with chronic diseases
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102093284B (en) * 2010-12-29 2013-05-08 宜昌人福药业有限责任公司 Method for enriching piperidine-2-formanilide optically active compound
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
CN106187864B (en) * 2016-07-11 2018-11-23 江苏天和制药有限公司 A method of high-purity Bupivacaine alkali is prepared by bupivacaine HCl
JP2023515918A (en) 2020-01-13 2023-04-17 デュレクト コーポレーション Sustained release drug delivery system with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
WO2023158722A2 (en) * 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processes for preparation of avacopan and intermediates thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2301498A1 (en) * 1975-02-20 1976-09-17 Maggioni & C Spa Racemisation of amino acids - esp. lysine, by refluxing in an aqueous solvent

Also Published As

Publication number Publication date
DE69628540T2 (en) 2004-01-08
PL321378A1 (en) 1997-12-08
NO308843B1 (en) 2000-11-06
FI117437B (en) 2006-10-13
MX9705428A (en) 1997-11-29
HU227426B1 (en) 2011-05-30
NO973312D0 (en) 1997-07-17
ZA96403B (en) 1997-01-20
AU4394896A (en) 1996-08-07
DE69628540D1 (en) 2003-07-10
EP0804417A1 (en) 1997-11-05
NO973312L (en) 1997-07-17
CA2208522A1 (en) 1996-07-25
ES2201166T3 (en) 2004-03-16
ATE242214T1 (en) 2003-06-15
DK0804417T3 (en) 2003-10-06
CA2208522C (en) 2007-03-13
BR9606821A (en) 1997-12-23
WO1996022281A1 (en) 1996-07-25
KR19980701432A (en) 1998-05-15
CN1172912C (en) 2004-10-27
AU701221B2 (en) 1999-01-21
GB9501071D0 (en) 1995-03-08
HUP9901418A3 (en) 2001-01-29
FI973040A0 (en) 1997-07-17
JP4015696B2 (en) 2007-11-28
PT804417E (en) 2003-09-30
CN1168134A (en) 1997-12-17
KR100404390B1 (en) 2004-01-31
PL184091B1 (en) 2002-08-30
EP0804417B1 (en) 2003-06-04
JPH11501905A (en) 1999-02-16
FI973040L (en) 1997-07-17

Similar Documents

Publication Publication Date Title
HUP9901418A2 (en) Procedure for the racemization of levobupivacaine and analogous active substances
DE69434148D1 (en) Alcohol dehydrogenase, DNA coding therefor, production and process for the production of optically active alcohols
EA199800857A1 (en) COMPOSITION FOR REMOVAL OF PAIN AND METHOD OF REMOVAL OF PAIN
IT1260468B (en) METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL
NO962874D0 (en) Preparation of bone for transplantation
ATE345682T1 (en) IN VITRO METHOD FOR INTRODUCING NUCLEIC ACIDS INTO A CELL
DE69629670D1 (en) LACTAM-CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEASES
ATE292959T1 (en) METHOD FOR PRODUCING MICROSPHERES CONTAINING HIGH STABILITY PANCREATIC ENZYME
DK314989D0 (en) PROCEDURE FOR THE PREPARATION OF OPTICALLY ACTIVE ALFA-SUBSTITUTED ORGANIC ACIDS, AND MICRO-ORGANISMS AND ENZYMES USED IN THE PROCEDURE
YU48666B (en) MOMETASON FUROAT MONOHYDRATE AND PROCEDURE FOR ITS PRODUCTION
ATE188256T1 (en) SURFACE LOCALIZED EXPRESSION OF ENZYMES IN GENE-CONTROLLED PRODRUG THERAPY
SE0001914L (en) Improving Peyronie's disease
UA26375A1 (en) METHOD OF PURIFICATION OF ISHULIH
NO960775L (en) Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections
BG102064A (en) Method for increasing the retinal blood circulation
DE3764700D1 (en) METHOD FOR PRODUCING AN AQUEOUS PHARMACEUTICAL SOLUTION OF AN ORGANIC ACID AS AN ACTIVE SUBSTANCE.
NO892125D0 (en) COMBINATION OF ANGIOTENSIN-CONVERSIBLE ENZYME INHIBITORS WITH POTASSIUM CHANNEL MODULATORS AND THEIR USE IN PHARMACEUTICALS.
ATE239736T1 (en) PRODUCTION OF CLAVUNALATE SALTS
HUP9802531A2 (en) Method of mobilizing hematopoietic stem cells
NO20022458D0 (en) Process for the preparation of optically active amines
DK325289A (en) STRONTIUM SALT, METHOD OF PREPARING IT, AND PHARMACEUTICAL AGENTS CONTAINING SALT
DE59106876D1 (en) Process for the enzymatic production of optically active cyanohydrins.
PT793666E (en) SILILLACTION PROCESS
DK1237537T3 (en) Preparation in the form of a gel for receiving an active substance in solution or suspension, especially for use on a mucosa, and process for its preparation
BR0009636B1 (en) process for the preparation of mature insulin or a derivative of mature insulin.